216 related articles for article (PubMed ID: 9723363)
1. Pharmacokinetic study of twice vs thrice daily dosing of Sandimmun Neoral in pediatric renal transplant patients.
Papachristou F; Gakis D; Sotiriou I; Liatsis I; Takoudas D; Antoniadis A
Transplant Proc; 1998 Aug; 30(5):1988-90. PubMed ID: 9723363
[No Abstract] [Full Text] [Related]
2. Sandimmun and Neoral treatment: pharmacokinetics and kidney function in paediatric and adolescent renal transplant.
De Palma MT; Giordano M; Colella V; Palumbo F; De Nicolo VE; Caringella DA
Transplant Proc; 1998 Aug; 30(5):1677. PubMed ID: 9723239
[No Abstract] [Full Text] [Related]
3. Safety and efficacy of conversion from once daily Sandimmun to twice daily Neoral cyclosporine in renal allograft recipients.
Vathsala A; Lee WT; Lu YM; Woo KT
Transplant Proc; 1998 Aug; 30(5):1746-8. PubMed ID: 9723264
[No Abstract] [Full Text] [Related]
4. Pharmacokinetic analysis of Neoral conversion in pediatric and adult renal transplant recipients with poor absorption of Sandimmune.
Pescovitz MD; Henson S; Bodziak K; Book BK; Gonin J; Jindal RM; Leapman SB; Milgrom ML; Filo RS
Transplant Proc; 1996 Aug; 28(4):2165-8. PubMed ID: 8769189
[No Abstract] [Full Text] [Related]
5. Comparative pharmacokinetic study of Neoral vs Sandimmun in Japanese stable renal allograft recipients.
Takahara S; Ohta K; Ohashi Y; Namii Y; Uchida K; Okuyama A; Kainuma H; Takagi H; Takahashi K; Morikawa H
Transplant Proc; 1999 Nov; 31(7):3089-92. PubMed ID: 10610595
[No Abstract] [Full Text] [Related]
6. A critical appraisal of cyclosporine A pharmacokinetics in pediatric kidney transplantation using a microemulsion galenic formulation (Neoral).
Foradori A; Pinto VM; Elberg A
Transplant Proc; 1998 Aug; 30(5):1666-7. PubMed ID: 9723235
[No Abstract] [Full Text] [Related]
7. Sandimmun-to-Neoral conversion in stable pediatric kidney transplant recipients.
Kelles A; Herman J; Tjandra-Maga TB; Van Damme-Lombaerts R
Transplant Proc; 1998 Aug; 30(5):1995-6. PubMed ID: 9723366
[No Abstract] [Full Text] [Related]
8. Comparative pharmacokinetic study of neoral versus Sandimmun in Japanese stable renal allograft recipients.
Takahara S; Ohta K; Ohashi Y; Namii Y; Uchida K; Okuyama A; Kainuma H; Takagi H; Takahashi K; Morikawa H
Transplant Proc; 2001 Jun; 33(4):2541-4. PubMed ID: 11406243
[No Abstract] [Full Text] [Related]
9. Use of Neoral in pediatric renal transplantation.
Ettenger RE; Smith HT; Kaiser B; Cooney GF; Summerauer J; Alexander S; Moulton LT; Choc MG; Wong RL
Transplant Proc; 1996 Aug; 28(4):2257-8. PubMed ID: 8769217
[No Abstract] [Full Text] [Related]
10. Estimated area-under-the-curve monitoring of Neoral in a stable pediatric renal transplant population: one-year experience.
Lemire J; Capparelli EV; MacDonald D; Benador N; Reznik VM; Mendoza SA; Griswold WR
Transplant Proc; 1998 Aug; 30(5):1983-4. PubMed ID: 9723361
[No Abstract] [Full Text] [Related]
11. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients.
Taesch S; Niese D
Transpl Int; 1994; 7 Suppl 1():S263-6. PubMed ID: 11271220
[TBL] [Abstract][Full Text] [Related]
12. Cyclosporine neoral pharmacokinetics in kidney and heart transplant patients.
Schiavelli R; Sgrosso JL; Sabbatiello R; Castro C; Ahualli L; Pattin M; Vazquez MC
Transplant Proc; 1996 Dec; 28(6):3343-4. PubMed ID: 8962299
[No Abstract] [Full Text] [Related]
13. Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients.
Løkkegaard H; Asmundsson P; Clausen P; Dieperink H; Hansen JM; Heaf J; Jensen SB; Kornerup HJ; Madsen S; Pedersen EB; Poulsen JV; Rasmussen K
Transplant Proc; 1996 Aug; 28(4):2199-201. PubMed ID: 8769199
[No Abstract] [Full Text] [Related]
14. Conversion to Sandimmun Neoral in stable renal transplant recipients over 1 year: hepatitis, liver dysfunction, dosing intervals, and therapeutic ranges.
Hsieh H; Chien YS; Hsu KT; Chung HM
Transplant Proc; 1998 Nov; 30(7):3552-4. PubMed ID: 9838555
[No Abstract] [Full Text] [Related]
15. Clinical study of sandimmun neoral in cadaveric renal transplantation.
Xue W; Chen Y; Xing J; Tian P
Transplant Proc; 1996 Jun; 28(3):1333-4. PubMed ID: 8658682
[No Abstract] [Full Text] [Related]
16. Comparison of Neoral and Sandimmune preparations in renal transplant patients--improved pharmacokinetics with neoral.
Warrens AN; Salama A; Waters JB; Lechler RI
Transplant Proc; 1996 Aug; 28(4):2169-70. PubMed ID: 8769190
[No Abstract] [Full Text] [Related]
17. Conversion from cyclosporine to Neoral in pediatric recipients for kidney, liver, and heart transplantation.
Holmberg C; Laine J; Jalanko H; Leijala M; Hoppu K
Transplant Proc; 1996 Aug; 28(4):2262-3. PubMed ID: 8769219
[No Abstract] [Full Text] [Related]
18. Cyclosporine pharmacokinetic profiles in stable renal allograft recipients converting from Sandimmun to Neoral.
Vathsala A; Lee WT; Jacob E; Woo KT
Transplant Proc; 1996 Jun; 28(3):1324-6. PubMed ID: 8658678
[No Abstract] [Full Text] [Related]
19. Optimizing Neoral therapeutic drug monitoring with cyclosporine trough (C(0)) and C(2) concentrations in stable renal allograft recipients.
Einecke G; Mai I; Diekmann F; Fritsche L; Boehler T; Neumayer HH; Budde K
Transplant Proc; 2001; 33(7-8):3102-3. PubMed ID: 11750333
[No Abstract] [Full Text] [Related]
20. The Swedish nationwide experience of converting transplant patients treated with Sandimmun to the new galenic formulation Sandimmun-neoral. The Swedish Sandimmun-Neoral Conversion Group.
Wilczek HE; Berglin E; Blohmé I; Bäckman L; Fehrman I; Källen R; Nyberg G; Säwe J; Wahlberg J
Transplant Proc; 1997; 29(1-2):280-3. PubMed ID: 9122995
[No Abstract] [Full Text] [Related]
[Next] [New Search]
